Author:
Bouligand Jérôme,Richard Clémentine,Valteau-Couanet Dominique,Orear Cedric,Mercier Lionel,Kessari Romain,Simonnard Nicolas,Munier Fabienne,Daudigeos-Dubus Estelle,Tou Bassim,Opolon Paule,Deroussent Alain,Paci Angelo,Vassal Gilles
Funder
Université Paris-Saclay
Académie nationale de médecine
Association de la recherche sur le cancer
Institute Gustave Roussy
Université Paris Sud
Fondation pour la Recherche Médicale
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Organic Chemistry,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biotechnology
Reference26 articles.
1. Meresse V, Hartmann O, Vassal G, Benhamou E, Valteau-Couanet D, Brugieres L, et al. Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children. Bone Marrow Transplant. 1992;10(2):135–41.
2. Grochow LB, Jones RJ, Brundrett RB, Braine HG, Chen TL, Saral R, et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol. 1989;25(1):55–61.
3. Slattery JT, Kalhorn TF, McDonald GB, Lambert K, Buckner CD, Bensinger WI, et al. Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients. J Clin Oncol. 1996;14(5):1484–94.
4. Bouligand J, Boland I, Valteau-Couanet D, Deroussent A, Kalifa C, Hartmann O, et al. In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa). Bone Marrow Transplant. 2003;32(10):979–86.
5. Ladenstein RL, Poetschger U, Luksch R, Brock P, Castel V, Yaniv I, et al. Busulphan-melphalan as a myeloablative therapy (MAT) for high-risk neuroblastoma: results from the HR-NBL1/SIOPEN trial. ASCO Meeting Abstracts. 2011;29 Suppl 15:2.
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献